Page 2 - Nasdaq Atra News Today

StockNews.com initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and set a $28.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, […]

HC Wainwright restated their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $28.00 target price on the biotechnology company’s stock. Separately, StockNews.com began coverage on shares of Atara Biotherapeutics in a report on Thursday, August […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) EVP Amar Murugan sold 8,672 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $1.65, for a total transaction of $14,308.80. Following the sale, the executive vice president now directly owns 265,391 shares of the […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CFO Eric J. Hyllengren sold 8,186 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $1.65, for a total value of $13,506.90. Following the completion of the sale, the chief financial officer now owns 217,956 […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totalling 11,700,000 shares, a decrease of 11.4% from the June 15th total of 13,200,000 shares. Based on an average daily volume of 1,940,000 shares, […]

HC Wainwright reiterated their buy rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report published on Wednesday morning, The Fly reports. HC Wainwright currently has a $28.00 price target on the biotechnology company’s stock, up from their prior price target of $27.00. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 12,620,000 shares, a decrease of 11.0% from the May 15th total of 14,180,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is […]

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to […]

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have earned a consensus recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the […]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 14,180,000 shares, a decrease of 20.3% from the April 30th total of 17,790,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio […]